TeloHealthDx has secured funding through a combination of private investments and competitive grants to support the development of our groundbreaking telomere profiling technologies. Our core technology was initially developed with support from a research grant (U01ES031786) from the National Institutes of Health (NIH) and funding from Georgetown University Medical Center.

​

In 2023, TeloHealthDx raised $50,000 from family and friends to further propel our research efforts. In 2024, we were awarded a competitive NIH STTR Phase I grant (R41AG085701), totaling $448,961, to develop a cost-effective and accurate telomere test for diagnosing Telomere Biology Disorders (TBD).

​

We are actively applying for SBIR Phase I and Phase II funding to support the continued development of telomere profiling tests aimed at diagnosing idiopathic pulmonary fibrosis (IPF) and myeloid leukemias.

​

For investors interested in partnering with us and contributing to the next phase of innovation in telomere diagnostics, please contact us for more information.